The following is from the USPTO data base dated Fe
Post# of 15624
(Total Views: 486)
Posted On: 10/24/2018 1:43:06 PM
The following is from the USPTO data base dated February 18, 2018. If I am reading this correctly, they have already tested the product on 100 subjects with psoriasis with positive results. If so, then I don't understand the Phase 2 that they talk about. Opinions welcome from all.
20180042890 CANNABIS-BASED EXTRACTS AND TOPICAL FORMULATIONS FOR USE IN SKIN DISORDERS
Sample Size:
[0388] Up to 100 subjects
Statistical Analysis:
[0389] Descriptive statistics is calculated for all data.
Results:
[0390] It appears from the results of the above described clinical study that in comparison to the placebo control, the cannabis oil composition of the present invention (i.e. cream formulation), comprising essentially THC or combinations of THC and CBD, positively affected psoriasis symptoms.
[0391] It is demonstrated that patients administered with the cannabis composition of the present invention, in a therapeutically effective dosage and according to a predetermined protocol, showed an improvement in psoriasis symptoms as measured by PASI (i.e. reduction of at least one PASI score) used for assessing changes in psoriasis severity.
20180042890 CANNABIS-BASED EXTRACTS AND TOPICAL FORMULATIONS FOR USE IN SKIN DISORDERS
Sample Size:
[0388] Up to 100 subjects
Statistical Analysis:
[0389] Descriptive statistics is calculated for all data.
Results:
[0390] It appears from the results of the above described clinical study that in comparison to the placebo control, the cannabis oil composition of the present invention (i.e. cream formulation), comprising essentially THC or combinations of THC and CBD, positively affected psoriasis symptoms.
[0391] It is demonstrated that patients administered with the cannabis composition of the present invention, in a therapeutically effective dosage and according to a predetermined protocol, showed an improvement in psoriasis symptoms as measured by PASI (i.e. reduction of at least one PASI score) used for assessing changes in psoriasis severity.
(1)
(0)